Furthermore, our previous study also demonstrated that arabinogalactan-type LBP-3 exhibited an ameliorative effect against DSS-induced colitis by inhibiting the activation of TLR4-MyD88-NF-κB signaling pathways and reshaping the gut microbiota, as well as improving SCFA generation [78]. This evidence concerns the gene TLR4 and colitis.